Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia

  • Youngjoo KwonEmail author


Benign prostatic hyperplasia (BPH) is a noncancerous growth of the prostate. BPH commonly occurs in elderly men. Lower urinary tract symptoms (LUTS) secondary to BPH (LUTS/BPH) have significant impacts on their health. Saw palmetto (Serenoa repens) extract (SPE) has been evaluated for its effectiveness in improvement of LUTS/BPH at preclinical and clinical levels. Potential mechanisms of actions include anti-androgenic, pro-apoptotic, and anti-inflammatory effects. However, SPE efficacy was inconsistent, at least partly due to a lack of a standardized SPE formula. A hexane extract (free fatty acids, > 80%) provided more consistent results. Free fatty acids (lauric acid) were effective in inhibition of 5α-reductase, and phytosterol (β-sitosterol) reduced prostatic inflammation. Multiple actions derived from different constituents may contribute to SPE efficacy. Evaluation of the clinical relevance of these bioactive components is required for standardization of SPE, thereby enabling consistent efficacy and recommendations for the use in the prevention and treatment of BPH.


Benign prostatic hyperplasia Fatty acids Phytosterol Saw palmetto extract Standardized formula 



This study was supported by a grant from the Ottogi Foundation (16-241).


  1. Abe M, Ito Y, Oyunzul L, Oki-Fujino T, Yamada S. Pharmacologically relevant receptor binding characteristics and 5alpha-reductase inhibitory activity of free fatty acids contained in saw palmetto extract. Biol. Pharm. Bull. 32: 646–650 (2009a)CrossRefGoogle Scholar
  2. Abe M, Ito Y, Suzuki A, Onoue S, Noguchi H, Yamada S. Isolation and pharmacological characterization of fatty acids from saw palmetto extract. Anal. Sci. 25: 553–557 (2009b)CrossRefGoogle Scholar
  3. Anderson ML. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCaP-FGC by natural astaxanthin and saw palmetto lipid extract in vitro. J. Herb Pharmacother. 5: 17–26 (2005)CrossRefGoogle Scholar
  4. Arruzazabala ML, Perez Y, Ravelo Y, Molina V, Carbajal D, Mas R, Rodriguez E. Effect of oleic, lauric and myristic acids on phenylephrine-induced contractions of isolated rat vas deferens. Indian J. Exp. Biol. 49: 684–688 (2011)Google Scholar
  5. Awad AB, Fink CS, Williams H, Kim U. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur. J. Cancer Prev. 10: 507–513 (2001)CrossRefGoogle Scholar
  6. Baron A, Mancini M, Caldwell E, Cabrelle A, Bernardi P, Pagano F. Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells. BJU Int. 103: 1275–1283 (2009)CrossRefGoogle Scholar
  7. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE, Jr., Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT, CAMUS Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: A randomized trial. JAMA 306: 1344–1351 (2011)CrossRefGoogle Scholar
  8. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL. Saw palmetto for benign prostatic hyperplasia. N. Engl. J. Med. 354: 557–566 (2006)CrossRefGoogle Scholar
  9. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: An 18-month follow-up. BJU Int. 85: 842–846 (2000)CrossRefGoogle Scholar
  10. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol study group. Lancet 345: 1529–1532 (1995)Google Scholar
  11. Bernichtein S, Pigat N, Camparo P, Latil A, Viltard M, Friedlander G, Goffin V. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon(R)) in a mouse model of prostate hyperplasia. Prostate 75: 706–722 (2015)CrossRefGoogle Scholar
  12. Booker A, Suter A, Krnjic A, Strassel B, Zloh M, Said M, Heinrich M. A phytochemical comparison of saw palmetto products using gas chromatography and (1) H nuclear magnetic resonance spectroscopy metabolomic profiling. J. Pharm. Pharmacol. 66: 811–822 (2014)Google Scholar
  13. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br. J. Urol. 66: 639–641 (1990)CrossRefGoogle Scholar
  14. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br. J. Clin. Pharmacol. 18: 461–462 (1984)CrossRefGoogle Scholar
  15. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev. Urol. 13: 147–150 (2011)Google Scholar
  16. Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur. Urol. 45: 773–780 (2004)CrossRefGoogle Scholar
  17. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D’Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37: 77–83 (1998)CrossRefGoogle Scholar
  18. Fagelman E, Lowe FC. Saw palmetto berry as a treatment for BPH. Rev. Urol. 3: 134–138 (2001)Google Scholar
  19. Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation 82: 244–252 (2011)CrossRefGoogle Scholar
  20. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 112: 432–441 (2013)CrossRefGoogle Scholar
  21. Goepel M, Hecker U, Krege S, Rubben H, Michel MC. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 38: 208–215 (1999)CrossRefGoogle Scholar
  22. Habib FK, Wyllie MG. Not all brands are created equal: A comparison of selected components of different brands of serenoa repens extract. Prostate Cancer Prostatic Dis. 7: 195–200 (2004)CrossRefGoogle Scholar
  23. Hostanska K, Suter A, Melzer J, Saller R. Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan) on human carcinoma cell lines. Anticancer Res. 27: 873–881 (2007)Google Scholar
  24. Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J. Steroid Biochem. Mol. Biol. 54: 273–279 (1995)CrossRefGoogle Scholar
  25. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-phyto study group. Br. J. Urol. 80: 427–432 (1997)CrossRefGoogle Scholar
  26. Latil A, Petrissans MT, Rouquet J, Robert G, de la Taille A. Effects of hexanic extract of Serenoa repens (Permixon(R) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 75: 1857–1867 (2015)CrossRefGoogle Scholar
  27. Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci. Rep. 7: 7984 (2017)CrossRefGoogle Scholar
  28. Lepor H. Nonoperative management of benign prostatic hyperplasia. J. Urol. 141: 1283–1289 (1989)CrossRefGoogle Scholar
  29. Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev. Urol. 7(Suppl 4): S3-S12 (2005)Google Scholar
  30. Lepor H. Medical treatment of benign prostatic hyperplasia. Rev. Urol. 13: 20–33 (2011)Google Scholar
  31. Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Urol. Clin. North Am. 43: 311–323 (2016)CrossRefGoogle Scholar
  32. Liu J, Shimizu K, Kondo R. Anti-androgenic activity of fatty acids. Chem. Biodivers. 6: 503–512 (2009)CrossRefGoogle Scholar
  33. MacDonald R, Tacklind JW, Rutks I, Wilt TJ. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): An updated cochrane systematic review. BJU Int. 109: 1756–1761 (2012)CrossRefGoogle Scholar
  34. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 100: 327–331 (2007)CrossRefGoogle Scholar
  35. Novara G, Giannarini G, Alcaraz A, Cozar-Olmo JM, Descazeaud A, Montorsi F, Ficarra V. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur. Urol. Focus. 2: 553–561 (2016)CrossRefGoogle Scholar
  36. Opoku-Acheampong AB, Penugonda K, Lindshield BL. Effect of saw palmetto supplements on androgen-sensitive LNCaP human prostate cancer cell number and syrian hamster flank organ growth. Evid.-Based Complement. Alternat. Med. 2016: 8135135 (2016)Google Scholar
  37. Penugonda K, Lindshield BL. Fatty acid and phytosterol content of commercial saw palmetto supplements. Nutrients 5: 3617–3633 (2013)CrossRefGoogle Scholar
  38. Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud JP. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv. Ther. 19: 297–306 (2002)CrossRefGoogle Scholar
  39. Raynaud JP, Cousse H, Martin PM. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J. Steroid Biochem. Mol. Biol. 82: 233–239 (2002)CrossRefGoogle Scholar
  40. Reece Smith H, Memon A, Smart CJ, Dewbury K. The value of Permixon in benign prostatic hypertrophy. Br. J. Urol. 58: 36–40 (1986)CrossRefGoogle Scholar
  41. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 22: 43–51 (1993)CrossRefGoogle Scholar
  42. Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev. Urol. 7(Suppl 9): S3–S14 (2005)Google Scholar
  43. Saad F, Yassin AA, Haider A, Gooren L. Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. Arab J. Urol. 9: 147–152 (2011)CrossRefGoogle Scholar
  44. Scaglione F, Lucini V, Pannacci M, Dugnani S, Leone C. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur. Rev. Med. Pharmacol. Sci. 16: 569–574 (2012)Google Scholar
  45. Scholtysek C, Krukiewicz AA, Alonso JL, Sharma KP, Sharma PC, Goldmann WH. Characterizing components of the saw palmetto berry extract (SPBE) on prostate cancer cell growth and traction. Biochem. Biophys. Res. Commun. 379: 795–798 (2009)CrossRefGoogle Scholar
  46. Silvestri I, Cattarino S, Agliano A, Nicolazzo C, Scarpa S, Salciccia S, Frati L, Gentile V, Sciarra A. Effect of Serenoa repens (Permixon(R)) on the expression of inflammation-related genes: Analysis in primary cell cultures of human prostate carcinoma. J. Inflamm. 10: 11 (2013)CrossRefGoogle Scholar
  47. Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, Ioiart I, Ambert V, Constantin T, Petrut B, Feciche B. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol. Int. 86: 284–289 (2011)CrossRefGoogle Scholar
  48. Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq W, Malice MP. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur. Urol. 26: 247–252 (1994)CrossRefGoogle Scholar
  49. Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B. Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J. Steroid Biochem. 20: 515–519 (1984)CrossRefGoogle Scholar
  50. Suzuki M, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, Noguchi H, Yamada S. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol. Sin. 30: 227–281 (2009)CrossRefGoogle Scholar
  51. Suzuki M, Oki T, Sugiyama T, Umegaki K, Uchida S, Yamada S. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 69: 1216–1220 (2007)CrossRefGoogle Scholar
  52. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 12: CD001423 (2012)Google Scholar
  53. Talpur N, Echard B, Bagchi D, Bagchi M, Preuss HG. Comparison of saw palmetto (extract and whole berry) and cernitin on prostate growth in rats. Mol. Cell Biochem. 250: 21–26 (2003)CrossRefGoogle Scholar
  54. Vela-Navarrete R, Alcaraz A, Rodriguez-Antolin A, Minana Lopez B, Fernandez-Gomez JM, Angulo JC, Castro Diaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero Garcia JM, Fernandez-Pro Ledesma A, Cozar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R))) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): Systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 122: 1049–1065 (2018)CrossRefGoogle Scholar
  55. Vela-Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J. Urol. 173: 507–510 (2005)CrossRefGoogle Scholar
  56. Vinarov AZ, Spivak LG, Platonova DV, Rapoport LM, Korolev DO. 15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression. Urologia (2018)
  57. von Holtz RL, Fink CS, Awad AB. Beta-sitosterol activates the sphingomyelin cycle and induces apoptosis in lncap human prostate cancer cells. Nutr. Cancer. 32: 8–12 (1998)CrossRefGoogle Scholar
  58. Wadsworth TL, Carroll JM, Mallinson RA, Roberts CT, Jr., Roselli CE. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 145: 3205–3214 (2004)CrossRefGoogle Scholar
  59. Weisser H, Tunn S, Behnke B, Krieg M. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28: 300–306 (1996)CrossRefGoogle Scholar
  60. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 3: CD001423 (2002)Google Scholar

Copyright information

© The Korean Society of Food Science and Technology 2019

Authors and Affiliations

  1. 1.Department of Food Science and EngineeringEwha Womans UniversitySeoulKorea

Personalised recommendations